Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Lantern Pharma received a USPTO Notice of Allowance for U.S. Patent Application No. 18/500,032 covering use of its drug candidate LP-284 to treat mantle cell lymphoma and double-hit lymphoma, including as a monotherapy and in combination with agents such as BTK, BCL2, and PARP inhibitors. Once issued, the method-of-treatment patent is expected to extend LP-284 patent protection into 2042, layering on top of composition-of-matter coverage into 2039 across major markets including the U.S., EU, Japan, and China.
Key figures
- Drug Name
- LP-284
- Phase Of Trial
- Phase 1a
- Trial id
- NCT06132503
- Patent application
- U.S. Patent Application No. 18/500,032 ('Method for Treating Blood Cancers')
- Ic50 min mcl cell line
- 88 nM (bortezomib-resistant MINO)
- Estimated annual market
- $4 billion
- Addressable patents annually
- 40,000 to 80,000 blood cancer patients
- Orphan drug designations lp284
- 3
- Method patent protection through
- 2042
- Composition patent protection through
- 2039
- Orphan drug designations pipeline total
- 6
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.